Addressing comorbidities and risk factors for tuberculosis (TB) is a crucial component of the World Health Organization (WHO)’s End TB Strategy. These consolidated guidelines on tuberculosis. Module 6: tuberculosis and comorbidities summarize the latest WHO recommendations on TB and key comorbidities. ...
These guidelines provide guidance on the diagnosis of HIV infection, the care of people living
with HIV and the use of antiretroviral (ARV) drugs for treating and preventing HIV infection.
They are structured along the continuum of HIV testing, prevention, treatment and care.
This edition updates the 201...
The primary audience for this guideline is national HIV programme managers, people living
with HIV, health-care providers and policy-makers in low- and middle-income countries. This
guideline update will be a useful resource for clinicians and should help to shape the priorities
of policy-makers in devel...
WHO promotes a public health approach to programming and delivering antiretroviral therapy (ART), which has enabled access to treatment and care for people living with HIV to be scaled up in resource-limited settings.
The 2016 WHO consolidated guidelines on the use of antiretroviral drugs for treating an...
Histoplasmosis is a disease caused by the fungus Histoplasma capsulatum. This disease is highly endemic in some regions of North America, Central America, and South America and is also reported in certain countries of Asia and Africa. It often affects people with impaired immunity, including people livin...
HIV is a chronic viral infection that damages the immune system. HIV can be contracted during sexual intercourse or through direct contact with the blood of an infected person (including sharing syringes). The virus can also be transmitted from mother to child during pregnancy, childbirth or breastfeedin...
Update on recommendations on antiretroviral regimens for treating and preventing HIV infection: In 2016, WHO published the consolidated guidelines on the use of antiretroviral (ARV) drugs for treating and preventing HIV infection and recommended tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) (or ...
This publication provides guidance on the public health response to pretreatment HIV drug resistance (HIVDR) to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) among people without prior antiretroviral (ARV) drug exposure or people with prior ARV exposure who are initiating or reinitiating first...
The objectives of these guidelines are to provide recommendations outlining a public health approach to managing people presenting with advanced HIV disease, and to provide guidance on the timing of initiation of antiretroviral therapy (ART) for all people living with HIV. The first set of recommendation...
WHO guidelines on HIV and Infant Feeding in 2010 for the first time recommended the use of antiretroviral drugs to prevent postnatal transmission of HIV through breastfeeding. This resulted in a major change from an individualised counselling approach toward a public health approach regarding how materna...
